Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study

Journal of Clinical Oncology

Volumn 34, Issue 10, 2016, Pages 1122-1130

  Armenian, Saro H ^a   Xu, Lanfang ^b   Ky, Bonnie ^c   Sun, Canlan ^a   Farol, Leonardo T ^b   Pal, Sumanta Kumar ^a   Douglas, Pamela S ^d   Bhatia, Smita ^e   Chao, Chun ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADULT ONSET CANCER; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER REGISTRY; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY CANCER; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; OBESITY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; RETROSPECTIVE STUDY; SMOKING; THYROID CANCER; UTERUS CANCER; ADVERSE EFFECTS; AGED; CALIFORNIA; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COMPLICATION; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; HEALTH INSURANCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOPLASM; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; NEOPLASMS; OBESITY; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; SURVIVORS;

EID: 84963533959     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.0409     Document Type: Article

References (40)

1. de Moor JS, Mariotto AB, Parry C, et al: Cancer survivors in the United States: Prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 22:561-570, 2013
2. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
3. DeSantis CE, Lin CC, Mariotto AB, et al: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64:252-271, 2014
4. Alagona P Jr, Ahmad TA: Cardiovascular disease risk assessment and prevention: Current guidelines and limitations. Med Clin North Am 99:711-731, 2015
5. Lipshultz SE, Adams MJ, Colan SD, et al: Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: Pathophysiology, course, monitoring, management, prevention, and research directions: A scientific statement from the American Heart Association. Circulation 128:1927-1995, 2013
6. [Erratum: Circulation 128:e394, 2013]
7. Rugbjerg K, Mellemkjaer L, Boice JD, et al: Cardiovascular disease in survivors of adolescent and young adult cancer: A Danish cohort study, 1943-2009. J Natl Cancer Inst 106: dju110, 2014
8. Ganz PA, Hussey MA, Moinpour CM, et al: Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. J Clin Oncol 26:1223-1230, 2008
9. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97:2869-2879, 2003
10. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
11. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
12. Hull MC, Morris CG, Pepine CJ, et al: Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 290:2831-2837, 2003
13. Chavez-MacGregor M, Zhang N, Buchholz TA, et al: Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31:4222-4228, 2013
14. Hershman DL, McBride RB, Eisenberger A, et al: Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 26:3159-3165, 2008
15. Doyle JJ, Neugut AI, Jacobson JS, et al: Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 23:8597-8605, 2005
16. O'Farrell S, Garmo H, Holmberg L, et al: Risk and timing of cardiovascular disease after androgendeprivation therapy in men with prostate cancer. J Clin Oncol 33:1243-1251, 2015
17. Limat S, Demesmay K, Voillat L, et al: Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 14:277-281, 2003
18. Baldini E, Prochilo T, Salvadori B, et al: Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: Focus on cardiac safety. Br J Cancer 91:45-49, 2004
19. Boerman LM, Berendsen AJ, van der Meer P, et al: Long-term follow-up for cardiovascular disease after chemotherapy and/or radiotherapy for breast cancer in an unselected population. Support Care Cancer 22:1949-1958, 2014
20. Ryberg M, Nielsen D, Cortese G, et al: New insight into epirubicin cardiac toxicity: Competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100:1058-1067, 2008
21. Hequet O, Le QH, Moullet I, et al: Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 22:1864-1871, 2004
22. Guarneri V, Lenihan DJ, Valero V, et al: Longterm cardiac tolerability of trastuzumab in metastatic breast cancer: The M. D. Anderson Cancer Center experience. J Clin Oncol 24:4107-4115, 2006
23. Koebnick C, Langer-Gould AM, Gould MK, et al: Sociodemographic characteristics of members of a large, integrated health care system: Comparison with US Census Bureau data. Perm J 16:37-41, 2012
24. Elliott MN, Fremont A, Morrison PA, et al: A new method for estimating race/ethnicity and associated disparities where administrative records lack self-reported race/ethnicity. Health Serv Res 43:1722-1736, 2008
25. Derose SF, Contreras R, Coleman KJ, et al: Race and ethnicity data quality and imputation using U. S. Census data in an integrated health system: The Kaiser Permanente Southern California experience. Med Care Res Rev 70:330-345, 2013
26. Chen LH, Quinn V, Xu L, et al: The accuracy and trends of smoking history documentation in electronic medical records in a large managed care organization. Subst UseMisuse 48:731-742, 2013
27. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
28. Tanvetyanon T, Padhya T, McCaffrey J, et al: Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol 27:1983-1991, 2009
29. Nanda A, Chen MH, Braccioforte MH, et al: Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302:866-873, 2009
30. Wang SY, Long JB, Hurria A, et al: Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer Res Treat 146:411-419, 2014
31. Yeh ET, Tong AT, Lenihan DJ, et al: Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation 109:3122-3131, 2004
32. Lenihan DJ, Cardinale DM: Late cardiac effects of cancer treatment. J Clin Oncol 30:3657-3664, 2012
33. Accordino MK, Neugut AI, Hershman DL: Cardiac effects of anticancer therapy in the elderly. J Clin Oncol 32:2654-2661, 2014
34. Basaria S: Cardiovascular disease associated with androgen-deprivation therapy: Time to give it due respect. J Clin Oncol 33:1232-1234, 2015
35. Hughes E, Kilmer G, Li Y, et al; Centers for Disease Control and Prevention (CDC): Surveillance for certain health behaviors among states and selected local areas - United States, 2008. MMWR Surveill Summ 59:1-221, 2010
36. Armstrong GT, Oeffinger KC, Chen Y, et al: Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 31:3673-3680, 2013
37. Chow EJ, Baker KS, Flowers ME, et al: Influence of metabolic traits and lifestyle factors on cardiovascular disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 18:S226-S227, 2012(suppl)
38. Armenian SH, Chow EJ: Cardiovascular disease in survivors of hematopoietic cell transplantation. Cancer 120:469-479, 2014
39. Bowles EJ, Wellman R, Feigelson HS, et al; Pharmacovigilance Study Team: Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 104:1293-1305, 2012
40. Allen LA, Yood MU, Wagner EH, et al; Pharmacovigilance Research Group: Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer. Med Care 52:e30-e38, 2014